Gut plays a vital role in the food processing system that includes the interaction between the immunity and diet. Gut disorders are extremely common, and can make an individual uncomfortable and have major impact on physiological function of the body. A few common gut disorders include IBS (irritable bowel syndrome), bloating, reflux, heartburn, nausea, diarrhea, constipation, and others; like Crohn’s disease and celiac disease. Gut disorders treatment, a lot of times, is not considered by the patients and is left to get resolved with time. The common gut disorders treatment include modification of the patient’s diet. According to various researches conducted worldwide, it has been concluded that grains that contain gluten create spaces in between the intestinal cells to open. The opening of these spaces cause the natural gut barrier compromised to various toxins, as well as undigested food. Furthermore, the WBCs (White Blood Cells) interact with the gut contents and could then, lead to local swelling, inflammation, or irritation in the intestines, leading to various gut disorders.
Increasing incidence of various gut disorders worldwide is expected to boost market demand for gut disorders treatment over the forecast period. Increasing cases of unhealthy lifestyle, stress and lifestyle-related diseases is also expected to create immense opportunities for the gut disorders treatment market. In addition, constant rise in the elderly population and increase research and developmental activities of the manufacturers in the gut disorders market is expected to propel market growth for gut disorders treatment during the forecast period. However, intense competition among the major players for increasing their revenue share in the gut disorders treatment market might cause price erosion which could further hinder the market growth for gut disorders treatment market over the forecast period. Lack of availability of gut disorders treatment in various developing countries and poor economy countries could also obstruct market growth for gut disorders treatment.
On the basis of Application, Gut Disorders Treatment Market can be segmented as:
On the basis of Form, Gut Disorders Treatment Market can be segmented as:
On the basis of End Use, Gut Disorders Treatment Market can be segmented as:
There have been several mergers, collaborations and distribution agreements between the market players in the gut disorders treatment market, which is creating a tremendous scope for the gut disorders treatment market and is expected to fasten the pace for the gut disorders treatment market during the forecast period. For instance, HiFiBiO Therapeutics collaborated with Takeda in July 2018, for the discovery of antibody therapies for potential gut disorders treatment, related cancer and other diseases. Also, Japan Patent office granted the patent to Pluristem Therapeutics for the ARS (Acute Radiation Syndrome) treatment and the related impact on the gastrointestinal tract. The distribution of gastrointestinal symptoms affects largely the population of middle and low-income countries and thus, varies across social class. For instance, peptic ulcer disease is linked to low socio-economic status. Increase in healthcare expenditure is likely to affect the gut disorders treatment market tremendously during the forecast period.
For a large number of gut disorders and related cancer lesions, the lifestyle choices and changes play a vital role for the gut disorders treatment. According to a study reported in Hepatology and Gastroenterology, In Asia, the cancers that were associated to the gastrointestinal system were most common in Asia Pacific region in 2010, majorly because of the high tobacco and alcohol use among all age groups. For developed countries like the United States, a decent number of the population pool highly suffered with various gut disorders that required gut disorders treatment, due to the lifestyle factors and morbid obesity. The United European Gastroenterology, in 2017, welcomed the MEP Digestive Health Group in the European parliament for raising awareness on chronic gut disorders treatment available. Growing awareness and government initiatives for gut disorders treatment is expected to boost market growth for gut disorders treatment in the Europe region.
Some of the market participants in the Global Gut Disorders Treatment market identified across the value chain include: Abbott Laboratories, AstraZeneca, Bayer AG, GlaxoSmithKline PLC, Johnson and Johnson Services, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Astellas Pharma Inc.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
Regional analysis includes